R&D News | pharmaphorum

News

Boehringer Ingelheim has started a phase 2 trial of a drug that could offer the first oral drug for geographic atrophy, a major cause of sight loss.

News

Gilead Sciences has joined the list of pharma groups hiking their capital investment plans in the US.

News

A project to use federal databases to identify the "root causes of autism" has been launched by HHS, but there are concerns about its credibility.

News

AstraZeneca and Daiichi Sankyo's Enhertu has been shown to provide a benefit in a phase 3 trial in early-stage breast cancer for the first time.

News

An AI model is being piloted at a national scale for the first time, but will it be able to predict future health risks reliably?

News

Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.